| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a7f3068c412965d1d753bd152f94fe
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0362
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2006-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6e80a79a25c402087f4bbfbd28e7a09d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_942bf722bd1d69a84d9c2effa359561f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d77415fe7d59a5bf13b9ac31d43c9d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4feea55290079ab642fc89bfbc7c666 |
| publicationDate |
2008-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1891237-A2 |
| titleOfInvention |
Enpp1 (pc-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications |
| abstract |
The present invention is directed to a method for determining if a subject is at increased risk to develop obesity or pathology related to obesity by determining the presence of a haplotype comprising three specific SNPs in a DNA or RNA sample of this subject and/or an elevated serum ENPP1 protein concentration. The present invention also relates to a kit and to an isolated nucleic sequence, vector or recombinant cell comprises said ENPP1 gene haplotype. The invention further comprises a method for selecting a compound for the treatment or the prevention of obesity or pathology related to obesity and a method for determining the efficacy of a drug to reduce the risk of obesity or pathology related to obesity in a patient. |
| priorityDate |
2005-06-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |